{"prompt": "['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'Pl: Lara Davis, MD', 'performed within the last 30 days. The early termination visit should include end of study', 'assessments listed in Section 5.8, Schedule of Events.', '5.7', 'UNSCHEDULED VISITS', 'Unscheduled study visits may occur at any time if medically warranted. Any assessments', 'performed at those visits should be recorded in the eCRF.', '23']['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', '5.8', 'SCHEDULE OF EVENTS', 'Follow', 'Procedures', 'Intervention Period (12 weeks [W])', 'Up*', 'Screening', 'Baseline*/W1', 'W2', 'W3', 'W4', 'W5', 'W6', 'W7', 'W8', 'W9', 'W10', 'W11', 'W12', 'Eligibility review', 'X', 'Treating physician evaluation', 'X', 'Informed Consent', 'X', 'Questionnaires', 'Physical Function: PROMIS-', 'X', 'X', 'PF/Cancer', 'Quality of Life: SF-36', 'X', 'X', 'Exercise: GLTEQ', 'X', 'X', 'Fatigue: FACT-F', 'X', 'X', 'Baseline demographics', 'X', 'Self-reported limitations', 'X', 'Adverse Events', 'X', 'Physical Tests', 'BMI - height + weight', 'X', 'X', 'Strength - 1RM', 'X', 'X', 'Strength - grip', 'Lower extremity function - short', 'X', 'X', 'PPB', 'Gait - iTUG', 'X', 'X', 'Balance - Sway', 'X', 'X', 'Gait/Balance - i6MWT', 'X', 'X', 'DXA', 'X', 'X', 'Urine hCG**', 'X', 'X***', 'In-Person Training', 'X', 'Videoconferenced PRT+', 'Independent PRT', 't Baseline assessments should occur within 14 days before initiating the exercise intervention; how ever, these assessments may be performed', 'during', 'Week', '1', 'prior', 'to', 'initiating exercise intervention', '+ The PRT regimen will consist of 2 one-hour training sessions per W eek (1 videoconference, 1 independent) for a total of 12 weeks (i.e., a total of 24 training', 'sessions).', '*12-w eek assessments may occur +14 days before or after completing the exercise intervention.', '**', 'Prior to DXA, for women of childbearing potential only.', '*** DXA,at follow-upv omit bone mineral density.', '24']['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'PI: Lara Davis, MD', '5.8.1 INCLUSION OF CHILDREN', 'This study will include participants that are aged >15 years. (Note: individuals in Oregon aged', '>15 years are able to consent to medical and dental services without consent of a legally', 'authorized representative (e.g., parent/legal guardian [ORS $109.640]).', '5.9', 'OHSU PARTICIPANT REGISTRATION PROCEDURES', 'Participants will be required to give written informed consent to participate in the study before', 'any screening tests or evaluations are conducted that are not part of standard care.', 'Registration from all consented participants must be entered into the OHSU electronic Clinical', 'Research Management System (CRMS, e.g., eCRIS). At a minimum, registration of OHSU', 'participants will include signed copies of the most recently Institutional Review Board (IRB)-', 'approved, informed consent form and HIPAA authorization.', '5.10 PARTICIPANT SCREENING AND ENROLLMENT', 'Potential participants will be screened using an IRB approved phone script. If eligible, an', 'appointment will be made for consenting and initial testing. In order to participate in this study,', 'signed informed consent must be obtained from the participant. The current IRB-approved', 'informed consent must be signed and dated by each participant prior to undergoing any study', 'procedures.', 'Baseline evaluations will begin once the participant has provided written informed consent to', 'participate in the study and ends when the participant initiates the study exercise regimen.', 'Study participants may be enrolled on to the study once all eligibility criteria are satisfied.', '5.11', 'PARTICIPANT WITHDRAWAL OR DISCONTINUATION FROM STUDY', 'INTERVENTION', 'Participants are free to withdraw consent and discontinue participation in the study at any time', 'and without prejudice to further treatment. If a participant no longer wishes to participate in the', 'interventional exercise regimen, but is willing to come for follow-up appointments, the', \"participant's request should be honored, if possible. The following are examples demonstrating\", \"why a participant's exercise intervention might be discontinued.\", 'Adverse effects of the assigned exercise intervention precludes further study participation.', 'Disease recurrence or progression.', \"Investigator's discretion.\", 'No further participant contact should be made if the participant withdraws consent for', 'participation in the study. Information about the reason(s) for discontinuation and collection of', 'any new or ongoing adverse events (AEs) should be collected at the time the participant', 'withdraws consent.', '5.11.1 HANDLING PARTICIPANT WITHDRAWAL AND DISCONTINUATION', 'Participants enrolled in this study that withdraw prior to initiating on-study exercise intervention', 'will be replaced. Participants that initiate on-study exercise intervention and subsequently', 'withdraw, will not be replaced.', '25']\n\n###\n\n", "completion": "END"}